IKK inhibition increases bortezomib effectiveness in ovarian cancer. - Test2 - elhamkhani - TriplyDB

IKK inhibition increases bortezomib effectiveness in ovarian cancer.

IKK inhibition increases bortezomib effectiveness in ovarian cancer.

http://www.wikidata.org/entity/Q36413454

about

Brain tissue banking for stem cells for our future Cancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and Prognosis of Prostate and Other Cancers Inflammatory related gene IKKα, IKKβ, IKKγ cooperates to determine liver cancer stem cells progression by altering telomere via heterochromatin protein 1-HOTAIR axis.Identification and characterization of a new source of adult human neural progenitors.Comparative analyses identify molecular signature of MRI-classified SVZ-associated glioblastoma.NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis.Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.The DLGAP family: neuronal expression, function and role in brain disorders.Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma.HDAC/IKK inhibition therapies in solid tumors.Epigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells.Positioning of proteasome inhibitors in therapy of solid malignancies.Targeting different domains of gap junction protein to control malignant glioma.Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells.Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy

P2860

Q28817010-A7FA63DF-329E-403A-8D9F-7FC435E7643C Q33624448-C11A1464-B43E-4419-845F-F35B0E9E360F Q36065765-10001F7A-5BB5-4979-BCD4-38FCD25AB7EC Q38630702-8726A085-5D66-4BD8-AEA2-0B1DAF058297 Q38712948-77ED20A4-6607-46BD-91C7-F27A16870B83 Q38730355-95FD8E75-E1C7-44FA-BC16-D1FBEA5BBD6A Q38975491-7A478CFC-F46F-41FA-A00C-4C9E6EFE5DEB Q41611100-E75FC623-5C85-4F25-BE9F-4152E7CE6B7F Q42261435-44702F47-2288-452A-A868-A98AF1B0B0AA Q42338747-D4CBC1C1-EB90-4CD7-B0D3-F0DD4341E1D6 Q42378478-6F252912-8611-4EC7-88AB-FBAAD08C3114 Q47353792-230EE584-DDDA-4A63-B198-BC62697FF39C Q47437730-15EE9588-A035-4D9F-8CAC-3A95954E00FD Q48363759-323FB382-F08C-479C-80AD-037593E1FDA4 Q58796147-3E61EC06-A588-4716-BB42-422E07F0C9C6

P2860

IKK inhibition increases bortezomib effectiveness in ovarian cancer.

http://www.wikidata.org/entity/Q36413454

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

IKK inhibition increases bortezomib effectiveness in ovarian cancer.

@ast

IKK inhibition increases bortezomib effectiveness in ovarian cancer.

@en

type

label

IKK inhibition increases bortezomib effectiveness in ovarian cancer.

@ast

IKK inhibition increases bortezomib effectiveness in ovarian cancer.

@en

prefLabel

IKK inhibition increases bortezomib effectiveness in ovarian cancer.

@ast

IKK inhibition increases bortezomib effectiveness in ovarian cancer.

@en

P1433

Q36413454-D7ADBE12-7195-49DB-AC5C-04C85CB0E8C7

P1476

Q36413454-6BD29759-A09E-482B-9668-0C7EA5EE43DE

P2093

Q36413454-0D9F6D92-844D-42EC-A9F6-1178FD88531C

Q36413454-5F0F0A3F-D068-487D-9F77-B2586FB77943

Q36413454-6CBD096F-B373-4EE8-BDF3-75BACF9AF55F

Q36413454-8302D35F-3AAF-46DC-A13C-780DE3903D56

Q36413454-89EE7A64-C2C0-4CA1-AF52-00FB03618DD4

P2860

Q36413454-015FE782-24BF-4BC5-A54D-73236C8D2465

Q36413454-076C16CF-31B0-4ED5-964E-7EE3EA44625B

Q36413454-078F870D-A571-4E9C-8B29-0C5E968B1498

Q36413454-0A82F267-6838-4F9D-821A-5445707A3C07

Q36413454-0DB4A8CC-819F-462F-9DB3-6263A6425392

Q36413454-1318D943-DF45-4186-9884-4E61194320F7

Q36413454-19D0CEE5-552E-4A84-88D3-CB8CA63387CD

Q36413454-1A7CFA74-45C6-400C-9D5A-5132868BA713

Q36413454-1ECE5E32-41E4-4A37-8C51-9940E3F2272D

Q36413454-212CB5CC-2DE9-4BAB-B410-2E7ABE1AC8CD

P304

Q36413454-C794BF1E-8C80-4A3B-BA32-43FC7B0D0BB5

P31

Q36413454-9BD53736-8075-4528-A186-B7B3367AAA48

P356

Q36413454-D5077974-2033-4815-9C3B-334CDF7EA233

Q36413454-E65280DF-155A-43D0-8310-862DD7EA0D3C

P407

Q36413454-AB6E787C-FB70-4883-93BA-245DEBD31C1B

P433

Q36413454-01DC67D5-0210-4715-8079-0834BF64162E

P478

Q36413454-B7051EEC-93AC-408D-B5AA-82E3F29575E7

P50

Q36413454-66A23835-630E-4F0B-A9A1-D46164C898FF

P577

Q36413454-59AF698A-EE28-4E54-8726-4CA486C7EE87

P698

Q36413454-C42CD0E1-5D33-4A03-8995-828E382E51DC

P921

Q36413454-1D16CCBE-CEDE-4BAB-BCF1-ED6566D0E403

P932

Q36413454-8FADB6B4-EED6-4F20-B589-A926E7E9A09E

P356

ONCOTARGET.4613

ONCOTARGET.4713

P1433

P1476

IKK inhibition increases bortezomib effectiveness in ovarian cancer.

@en

P2093

Atish Patel

http://www.w3.org/2001/XMLSchema#string

Bipradeb Singha

http://www.w3.org/2001/XMLSchema#string

Himavanth Reddy Gatla

http://www.w3.org/2001/XMLSchema#string

Ivana Vancurova

http://www.w3.org/2001/XMLSchema#string

Sai Phyo

http://www.w3.org/2001/XMLSchema#string

P2860

Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase

Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells

Transcriptional regulation of chemokine expression in ovarian cancer

Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation

The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta

Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.

The biology of ovarian cancer: new opportunities for translation

How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex.

Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer.

Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-κB inhibitors in ovarian cancer therapy.

P304

26347-26358

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.4613

http://www.w3.org/2001/XMLSchema#string

10.18632/ONCOTARGET.4713

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26267322

http://www.w3.org/2001/XMLSchema#string

P921

P932

4694906

http://www.w3.org/2001/XMLSchema#string